Anna Lembke is a Professor of Psychiatry at the Stanford University School of Medicine and chief of the Stanford Addiction Medicine Dual Diagnosis Clinic. Her work centers on addiction medicine, psychiatry, and dopamine-related behaviors, and she is the author of 'Dopamine Nation: Finding Balance in the Age of Indulgence'. Her published research focuses on substance use disorders, examining treatments for opioid and alcohol dependence, associated cardiovascular risks, and the use of machine learning and social media data to monitor addiction trends.
The universal symptoms of withdrawal from any addictive substance or behavior are anxiety, irritability, insomnia, depression, and craving.
"experiencing the universal symptoms of withdrawal from any addictive substance or behavior, which are anxiety, irritability, insomnia, depression, and craving." (said at 0:23:47)
Neurobiological models of addiction characterize the withdrawal/negative affect stage across addictive substances and behavioral addictions by a common motivational withdrawal syndrome. This state is marked by negative emotional symptoms including anxiety, irritability, dysphoria or depression, craving, and sleep disturbances. However, labeling these exact five symptoms as universal across every addiction requires qualification: physical and acute withdrawal profiles vary markedly depending on the substance (for example, acute stimulant withdrawal is typically characterized by hypersomnia rather than insomnia, whereas sedative-hypnotic and opioid withdrawal produce pronounced autonomic and somatic symptoms).
The average lifespan of a business is currently around 15 years, compared to 50 years approximately 50 years ago.
"I I recently read that the the average life of a business now is like 15 years, whereas, you know, 50 years ago it was 50 years." (said at 0:52:24)
The statement reflects findings widely cited from corporate longevity studies conducted by consultancy firms such as Innosight and researchers like Richard Foster. These analyses examine the average tenure (or rolling average lifespan) of companies listed on the S&P 500 index, showing that average tenure dropped from roughly 50–60 years in the 1950s/1960s to under 20 years (around 15 to 18 years) in recent decades. However, qualifying context is necessary: this statistic measures the duration a large corporation remains on a specific stock market index (the S&P 500) prior to being removed due to mergers, acquisitions, or market cap changes, rather than the true operational lifespan or bankruptcy of all businesses in general (the vast majority of which are small enterprises with average lifespans under 10 years).
Withdrawal symptoms and intense cravings following sugar cessation typically last for approximately two weeks.
"And when we quit sugar, we have a comedown, right? We go into withdrawal, and it's manifested in all the different ways that we've talked about. And it lasts for about two weeks, and one of the most salient symptoms is intense craving for sugar." (said at 1:58:41)
While scientific literature and clinical studies confirm that attempts to reduce or cease sugar intake can lead to withdrawal-like symptoms—including low energy, depressed mood, body aches, and prominent sugar cravings—there is no fixed or standardized timeline establishing that these symptoms typically last for two weeks across the population. Ecological momentary assessment (EMA) research evaluating symptom trajectories during sugar reduction demonstrates that individuals experience substance-use-disorder-like symptoms (e.g., cravings, preoccupation, fatigue, low mood) during quitting attempts, but symptom burden varies significantly based on individual factors such as baseline sugar intake, food addiction traits, BMI, and psychological distress. Moreover, the construct of sugar addiction itself remains debated in clinical science.